Historical Overview of Biologic Response Modifiers

References

• Nowotny A. Antitumor effects of endotoxins. Handbook of Endotoxin, Vol. 3, Cellular Biology of Endotoxin, LJ Berry. Elsevier Science Inc., New York 1985; 389–448
   Google Scholar
• Coley W B. The treatment of malignant tumors by repeated inoculations of erysipelas: with a report of ten original cases. Am J Med Sci 1893; 105: 487–511
   Google Scholar
• Wiemann B, Starnes C O. Coley's toxins, tumor necrosis factor and cancer research: a historical perspective. Pharmacol Ther 1994; 64: 529–564
   PubMed Web of Science ®Google Scholar
• Coley W B. The treatment of inoperable sarcoma by bacterial toxins (the mixed toxins of the streptococcus of erysipelas and the bacillus prodigiosus). Practitioner 1909; 83: 589–613
   Google Scholar
• McKenzie R C, Sauder D N. Keratinocyte cytokines and growth factors—functions in skin immunity and homeostasis. Dermat Clin 1990; 8: 649–661
   PubMed Web of Science ®Google Scholar
• Usami H, Yamamoto A, Yamashita W. Antitumor effects of streptococcal lipoteichoic acids on Meth A fibrosarcoma. Br J Cancer 1988; 57: 70–73
   PubMed Web of Science ®Google Scholar
• Mihich E., Westphal O, Luderitz O. The tumor necrotizing effect of lipid A component of Escherichia coli endotoxin. Proc Soc Exp Biol Med 1961; 107: 816–819
   PubMed Web of Science ®Google Scholar
• Carswell E A, Old L J, Kassel R L. An endotoxin-induced serum factor that causes necrosis of tumors. Proc Natl Acad Sci USA 1975; 72: 3666–3670
   PubMed Web of Science ®Google Scholar
• Coley W B. Treatment of inoperable malignant tumors with the toxines of erysipelas and the bacillus prodigiousus. Trans Am Surg Assoc 1894; 12: 183–212
   Google Scholar
• Clowes G HA. A study of the influence exerted by a variety of physical and chemical forces on the virulence of carcinoma in mice and of the conditions under which immunity against cancer may be experimentally induced in these animals. Br Med J 1906; 2: 1548–1554
   Google Scholar
• Johnston B J, Novales E T. Clinical effect of Coley's toxin. II. A seven-year study. Cancer Chem Rep 1962; 21: 43–68
   PubMedGoogle Scholar
• Berendt M J, North R J, Kirstein D P. The immunological basis of endotoxin-induced tumor regression—requirement for a pre-existing state of concomitant anti-tumor immunity. J Exp Med 1978; 148: 1560–1569
   PubMed Web of Science ®Google Scholar
• Prehn R T, Main J M. Immunity to methylcholanthrene-induced sarcomas. J Natl Cancer Inst 1957; 18: 769–778
   PubMed Web of Science ®Google Scholar
• Prehn R T. Tumor antigens. Immunity, Cancer and Chemotherapy, E Mihich. Academic Press, New York 1967; 265–279
   Google Scholar
• Klein G, Sjogren H O, Klein E. Demonstration of resistance against methylcholanthrene-induced sarcomas in the primary autochthonous host. Cancer Res 1960; 20: 1561–1572
   PubMed Web of Science ®Google Scholar
• Mihich E. Modification of tumor regression by immunologic means. Cancer Res 1969; 29: 2345–2352
   PubMed Web of Science ®Google Scholar
• Biological Response Modifiers: Subcommittee Report. Natl Cancer Inst Monogr 63, NIH Publication No 83–2606, E Mihich, A Fefer. U.S. Dept of Health and Human Services, NCI, Bethesda, MD 1983
   Google Scholar
• Carey T E, Takahashi T, Resnick L A. Cell surface antigens of human malignant melanoma: Mixed hemadsorption assays for humoral immunity to cultured autologous melanoma cells. Proc Natl Acad Sci USA 1976; 73: 3278–3282
   PubMed Web of Science ®Google Scholar
• Brown J M, Rosenberg S A. Serologic analysis of human solid tumor antigens. Immunological Approaches to Cancer Therapeutics, E Mihich. John Wiley & Sons, New York 1982; 1–38
   Google Scholar
• Coulie P G, Van den Eynde BJ., Van der Bruggen P. Characterization of antigens recognized by T cells on human tumors. The Biology of Tumors, E Mihich, C Croce. Plenum Press, New York 1998; 173–183
   Google Scholar
• Pfreundschuh M, Tureci O, Sahin U. Identification of human tumor antigens using the B-cell repertoire. The Biology of Tumors, E Mihich, C Croce. Plenum Press, New York 1998; 185–198
   Google Scholar
• Restifo NP, Wunderlich J R. Biology of cellular immune responses. Biologic Therapy of Cancer, 2nd ed, VT DeVita, S Hellman, SA Rosenberg. J.B. Lippincott, Philadelphia 1995; 3–37
   Google Scholar
• Rosenberg S A. Adoptive immunotherapy of cancer using lymphokine activated killer cells and recombinant interleukin-2. Important Advances in Oncology, VT DeVita, S Hellman, SA Rosenberg. J.B. Lippincott, Philadelphia 1986; 55–91
   Google Scholar
• Visseren M JW, Van der Burg S H, Vierboom M E. T-cell and NK-mediated surveillance of cancer: a delicate balancing act. The Biology of Tumors, E Mihich, C Croce. Plenum Press, New York 1998; 249–271
   Google Scholar
• Herberman R B, Santoni A. Regulation of natural killer cell activity. Biological Responses in Cancer, E Mihich. Plenum Press, New York 1984; 121–144
   Google Scholar
• Lanier L L. Natural killer cells: from no receptors to too many. Immunity 1997; 6: 371–378
   PubMed Web of Science ®Google Scholar
• Parham P. NK cells, MHC class I antigens and missing self. Immunol Rev 1997; 155: 1–221
   Google Scholar
• Schwartzentruber D J, Marincola F M, Rosenberg S A. Biologic therapy with interleukin-2: clinical applications. Biologic Therapy of Cancer, 2nd ed, VT DeVita, S Hellman, SA Rosenberg. J.B. Lippincott, Philadelphia 1995; 235–278
   Google Scholar
• Foon K A, Savage P D, Muss H B. Biologic therapy with interferon-α and β: clinical applications. Biologic Therapy of Cancer, 2nd ed, VT DeVita, S Hellman, SA Rosenberg. J.B. Lippincott, Philadelphia 1995; 365–434
   Google Scholar
• Fraker D L, Alexander R H, Pass H I. Biologic therapy with TNF: systemic administration and isolation-perfusion. Biologic Therapy of Cancer, 2nd ed, VT DeVita, S Hellman, SA Rosenberg. J.B. Lippincott, Philadelphia 1995; 329–345
   Google Scholar
• Atkins M B, Mier J W, Trehu E G. Combination cytokine therapy: In: Biologic Therapy of Cancer, 2nd ed, VT DeVita, S Hellman, SA Rosenberg. J.B. Lippincott, Philadelphia 1995; 443–466
   Google Scholar
• Atkins M B, Robertson M J, Gordon M. Phase I evaluation of intravenous recombinant human interleukin 12 in patients with advanced malignancies. Clin Cancer Res 1998; 4: 1203–1213
   PubMedGoogle Scholar
• Hurwitz A A, Leach D R, Van Elsas A. Manipulation of T cell activation in the anti-tumor immune response. The Biology of Tumors, E Mihich, C Croce. Plenum Press, New York 1998; 213–230
   Google Scholar
• Cavallo F, Boggio K, Giovarelli M. Cytokines and tumor immunogenicity: toward an appropriate cancer vaccine. The Biology of Tumors, E Mihich, C Croce. Plenum Press, New York 1998; 231–247
   Google Scholar
• Fefer A, Cheever M A, Greenberg P D. Lymphocyte transfer as potential cancer immunotherapy. Immunological Approaches to Cancer Therapeutics, E Mihich. John Wiley & Sons, New York 1982; 333–362
   Google Scholar
• Rosenberg S A. Cell transfer therapy: clinical applications. Biologic Therapy of Cancer, 2nd ed, VT DeVita, S Hellman, SA Rosenberg. J.B. Lippincott, Philadelphia 1995; 487–521
   Google Scholar
• Mihich E, Ehrke M J, Ishizuka M. Immunomodulation by antibiotics. Biological Responses in Cancer, E Mihich, Y Sakurai. Plenum Press, New York 1985; 71–93
   Google Scholar
• Mihich E. Biological response modifiers: their potential and limitations in cancer therapeutics. Cancer Invest 1985; 3: 71–83
   PubMed Web of Science ®Google Scholar
• Spreafico F., Vecchi A. The immunomodulatory activity of certain cancer chemotherapeutic agents. Biological Responses in Cancer, E Mihich, Y Sakurai. Plenum Press, New York 1985; 131–154
   Google Scholar
• Mihich E, Ehrke M J. Immunomodulation by anticancer drugs. Biologic Therapy of Cancer, VT DeVita, S Hellman, SA Rosenberg. J.B. Lippincott., Philadelphia 1991; 776–786
   Google Scholar
• Mihich E. Future perspectives for biological response modifiers: a viewpoint. Semin Oncol 1986; 13: 234–254
   PubMed Web of Science ®Google Scholar
• Mastrangelo M J, Berd D. immunotherapy with microbial products. Immunological Approaches to Cancer Therapeutics, E Mihich. John Wiley & Sons, New York 1982; 75–105
   Google Scholar
• Chirigos M A, Mastrangelo M J. Immunorestoration by chemicals. Immunological Approaches to Cancer Therapeutics, E Mihich. John Wiley & Sons, New York 1982; 191–239
   Google Scholar
• Renoux G, Renoux M. Effet immunostimulant d'un imidothiazole dans I'immunisation des souris contre 1′infection par Brucella abortus. CR Acad Sci 1971; 2720: 349
   Google Scholar
• Laurie J A, Moertel C G, Fleming T R. Surgical adjuvant therapy of large bowel carcinoma: an evaluation of levamisole and the combination of levamisole and 5-flurouracil. A study of the North Central Cancer Treatment Group and Mayo Clinic. J Clin Oncol 1989; 7: 1447–1456
   PubMed Web of Science ®Google Scholar
• Moertel C G, Fleming T R, Macdonald J S. Fluorouracil plus levamisole as effective adjuvant therapy after resection of stage III colon carcinoma: a final report. Ann Intern Med 1995; 122: 321–326
   PubMed Web of Science ®Google Scholar
• Fidler U, Fogler W, Tarcsay L. Systemic activation of macrophages and treatment of cancer metastases by liposomes containing hyseophilix oelipophilix muramyl dipeptide. Adv Immunopharmacal 1983; 2: 235–241
   Google Scholar
• MacEwen E G, Kurzman I D, Rosenthal R C. Therapy for osteosarcoma in dogs with intravenous injection of liposome-encapsulated muramy1 tripeptide. J Natl Cancer Inst 1989; 81: 935–938
   PubMed Web of Science ®Google Scholar
• Kleinerman E S. Biologic therapy for osteosarcoma using liposome-encapsulated muramyl tripeptide. Hematol Oncol Clin North Am 1995; 9: 927–938
   PubMed Web of Science ®Google Scholar
• Hersh E M. Immunosuppressive agents. Antineoplastic and Immunosuppressive Agents I, AC Sartorelli, DG Johns. Springer-Verlag, New York 1974; 577–617
   Google Scholar
• Mihich E. Drug selectivity in the suppression of the immune response. Drugs and Immune Responsiveness, JL Turk, D Parker. Macmillan, London 1979; 25–39
   Google Scholar
• Shand F L, Liew F. Differential sensitivity to cyclophosphamide of helper T cells for humoral responses and suppressor T cells for delayed-type hypersensitivity. Eur J Immunol 1980; 10: 480–483
   Web of Science ®Google Scholar
• Maguire HC, Jr, Ettore V L. Enhancement of dinitrochlorobenzene (DNCB) contact sensitization by cyclophosphamide in the guinea pig. J Invest Dermatol 1967; 48: 39–43
   PubMed Web of Science ®Google Scholar
• Schwartz R S. Alteration of immunity by antimetabolites. Immunity, Cancer and Chemotherapy, E Mihich. Academic Press, New York 1967; 203–215
   Google Scholar
• Mullins DW., Alleva D G, Burger C J. Taxol, a microtubule stabilizing antineoplastic agent, differentially regulates normal and tumor-bearing host macrophage nitric oxide production. Immunopharmacology 1997; 37: 63–73
   PubMed Web of Science ®Google Scholar
• Berd D, Maguire HC, Jr, Mastrangelo M J. Immunopotentiation by cyclophosphamide and other cytotoxic agents. Immune Modulating Agents and their Mechanisms;, RL Fenichel, MA Chirigos. Marcel Dekker, New York 1984; 39–61
   Google Scholar
• Ehrke M J, Mihich E. Immunoregulation by cancer chemotherapeutic agents. Reticuloendoethelial System: A Comprehensive Treatise, Vol. 8; The Pharmacology of the Reticuloendoethial System, JW Hadden, A Szentivanyi. Plenum Press, New York 1985; 309–347
   Google Scholar
• Ehrke M J, Mihich E, Berd D. Effects of anticancer drugs on the immune system in man. Semin Oncol 1989; 16: 230–253
   PubMed Web of Science ®Google Scholar
• Ehrke M J, Mihich E. Adriamycin and other anthracyclines. Clinics in Immunology and Allergy, Vol. 4, Immune Suppression and Modulation, MS Mitchell, JL Fahey. Saunders, London 1984; 259–277
   Google Scholar
• Ehrke M J, Ho R LX, Mihich E. Modifications of antitumor immune effectors by adriamycin. Proc Int Symposium on New Horizons in Tumor Immunotherapy, M Torisu, T Yoshida. Elsevier, Amsterdam 1989; 467–475
   Google Scholar
• Zaleskis G, Berleth E, Ehrke M J. Doxorubicin induced DNA degradation in murine thymocytes. Mol Pharmacol 1994; 46: 901–908
   PubMed Web of Science ®Google Scholar
• Ho R LX, Maccubbin D, Zaleskis G. Development of a safe and effective adriamycin plus Interleukin 2 therapy against both adriamycin sensitive and resistant lymphomas. Oncol Res 1993; 5: 373–381
   PubMed Web of Science ®Google Scholar
• Ho R LX, Maccubbin D, Ujhazy. Immunological responses critical to the therapeutic effects of adriamycin plus interleukin 2 in C57B1/6 mice bearing syngeneic EL4 lymphomas. Oncol Res 1993; 5: 363–372
   PubMed Web of Science ®Google Scholar
• Ehrke M J, Verstovsek S, Zaleskis G. Demonstration of long-term specific anti-primary EL4 lymphoma immunity in 2-year old cured mice. Cancer Immunol Immunother 1996; 42: 221–230
   PubMed Web of Science ®Google Scholar
• Berleth E, Ujhazy P, Henn A. Doxorubicin (DOX)-induced immunomodulation of murine peritoneal exudate cells (PECs): Effect on cytokine mRNA levels and secreted protein. Proc AACR 1997; 38: 119
   Google Scholar
• Arinaga S, Akiyoshi T, Tsuji H. Augmentation of the generation cell mediated cytotoxicity after a single dose of Adriamycin in cancer patients. Cancer Res 1986; 46: 4213–4216
   PubMed Web of Science ®Google Scholar
• Borden E C, Edwards B S, Hawkins M J. Interferons: biological response modification and pharmacology. Biological Responses in Cancer, E Mihich. Plenum Press, New York 1984; 169–218
   Google Scholar
• Williamson B D, Carswell E A, Rubin B Y. Human tumor necrosis factor produced by human B-cell lines: synergistic cytotoxic interaction with human interferon. Proc Natl Acad Sci USA 1983; 80: 5397–5401
   PubMed Web of Science ®Google Scholar
• Lynch D H. The role of FasL and TNF in the homeostatic regulation of immune responses. Adv Exp Med Biol 1996; 406: 135–138
   PubMedGoogle Scholar
• Gruss H J. Molecular, structural and biological characteristics of the tumor necrosis factor ligand superfamily. Int J Clin Lab Res 1996; 26: 143–159
   PubMedGoogle Scholar
• Hori K, Ehrke M, Mace K. Effect of tumor necrosis factor on the induction of macrophage tumoricidal activity. Cancer Res 1987; 47: 2793–2798
   PubMed Web of Science ®Google Scholar
• Schulze-Osthoff K, Ferrari D, Los M. Apoptosis signaling by death receptors. Eur J Biochem 1998; 254: 439–459
   PubMedGoogle Scholar
• Sasajima T, Mineura K, Sasaki J. Positron emission toniographic assessment of cerebral hemocirculation and glucose metabolism in malignant glioma following treatment with intracarotid recombinant human tumor necrosis factor-alpha. J Neuro-Oncol 1995; 23: 67–73
   PubMed Web of Science ®Google Scholar
• Ehrke M J, Verstovsek S, Ujhazy P. Doxorubicin plus tumor necrosis factor-α combination treatments in E14 lymphoma-bearing C57B1/6 mice. Cancer Immunol Immunother 1998; 45: 287–298
   PubMed Web of Science ®Google Scholar
• Mizel S B. The interleukins: regulation of lymphocyte differentiation, proliferation and functional activation. Biological Responses in Cancer, E Mihich. Plenum Press, New York 1984; 89–119
   Google Scholar
• Nadler S H, Moore G E. Clinical immunologic study of malignant disease: response to tumor transplants and transfer of leukocytes. Ann Surg 1966; 164: 482–490
   PubMed Web of Science ®Google Scholar
• Cheever M A, Greenberg P D, Fefer A. Lymphocyte transfer for cancer therapy: prerequisites for efficacy and the use of long-term cultured T lymphocytes. Biological Responses in Cancer, E Mihich. Plenum Press, New York 1984; 145–183
   Google Scholar
• Cowens J W, Ozer H, Ehrke M J. Inhibition of the development of suppressor cells in culture by 4-hydroperoxycyclophosphamide. J Immunol 1984; 132: 95–100
   Web of Science ®Google Scholar
• Turk J L, Parker D, Poulter L W. Functional aspects of the selective depletion of lymphoid tissue by cyclophosphamide. Immunology 1972; 23: 493–501
   PubMed Web of Science ®Google Scholar
• Old L J. Cancer immunology: the search for specificity—GHA Clowes Memorial Lecture. Cancer Res 1981; 47: 261–275
   Google Scholar
• Kohler G, Milstein C. Continuous cultures of fused cells secreting antibody of predefined specificity. Nature 1975; 256: 495–497
   PubMed Web of Science ®Google Scholar
• Houghton A N, Chapman P B. Clinical applications of monoclonal antibodies in cancer: melanoma. Biologic Therapy of Cancer. 2nd ed, VT DeVita, S Hellman, SA Rosenberg. J.B. Lippincott, Philadelphia 1995; 576–590
   Google Scholar
• Miller R A, Maloney D G, Warnicki E R. Treatment of B cell lymphoma with monoclonal anti-idiotype antibody. N Engl J Med 1982; 306: 517–522
   PubMed Web of Science ®Google Scholar
• Davis T A, Maloney D G, Czerwinski D K. Anti-idiotype antibodies can induce long-term complete remissions in non-Hodgkin's lymphoma without eradicating the malignant clone. Blood 1998; 92: 1184–1190
   PubMed Web of Science ®Google Scholar
• Livingston P O, Oettgen H F, Old L J. Specific active immunotherapy in cancer treatment. Immunological Approaches to Cancer Therapeutics, E Mihich. John Wiley & Sons, New York 1982; 363–404
   Google Scholar
• Hanna MG, Jr, Peters L C, Hoover HC, Jr. Immunotherapy by active specific immunization: basic principles and preclinical studies. Biologic Therapy of Cancer, VT DeVita, S Hellman, SA Rosenberg. J.B. Lippincott, Philadelphia 1991; 651–669
   Google Scholar
• Berd D, Maguire HC, Jr, McCue P. Treatment of metastatic melanoma with an autologous tumor-cell vaccine: clinical and immunologic result in 64 patients. J Clin Oncol 1990; 8: 1858–1867
   PubMed Web of Science ®Google Scholar
• Mitchell M S, Kan-Mitchell J., Kempf R A. Active specific immunotherapy for melanoma: Phase I trial of allogeneic lysates and a novel adjuvant. Cancer Res 1988; 48: 5883–5893
   PubMed Web of Science ®Google Scholar
• Morton D L, Foshag L J, Nizze J A. Active specific immuno therapy in malignant melanoma. Semin Surg Oncol 1989; 5: 420–425
   PubMed Web of Science ®Google Scholar
• Sahasrabudhe D M, DeKernion J B, Pontes J E. Specific immunotherapy with suppressor function inhibition for metastatic renal carcinoma. J Biol Response Mod 1986; 5: 581–594
   PubMedGoogle Scholar
• McCune C S, Schapira D V, Henshaw E C. Specific immunotherapy of advanced renal carcinoma: Evidence for the polyclonality of metastases. Cancer 1984–1987; 47, 1981
   Google Scholar
• Mihich E. Tumor immunogenicity in therapeutics. Drug Resistance and Selectivity, E Mihich. Academic Press., New York 1973; 391–412
   Google Scholar
• Kobayashi H. The biological modification of tumor antigenicity in therapeutics: increase in immunologic foreignness of tumor cells in experimental model systems. Immunological Approaches to Cancer Therapeutics, E Mihich. John Wiley & Sons, New York 1982; 405–440
   Google Scholar
• Schlom J, Kantor J, Abrams S. Strategies for the development of recombinant vaccines for the immunotherapy of breast cancer. Breast Cancer Res Treat 1996; 38: 27–39
   PubMed Web of Science ®Google Scholar
• Mukherij B, Chakraborty N G, Yamashi S. Induction of antigen-specific cytolytic T cells in situ in human melanoma by immunization with synthetic peptide-pulsed autologous antigen presenting cells. Proc Natl Acad Sci USA 1995; 92: 8078–8082
   PubMed Web of Science ®Google Scholar
• Boczkowski D, Nair S K, Snyder D. Dendritic cells pulsed with RNA are potent antigen-presenting cells in vitro and in vivo. J Exp Med 1996; 184: 465–472
   PubMed Web of Science ®Google Scholar
• Gilboa E, Nair S K, Lyerly H K. Immunotherapy of cancer with dendritic-cell-based vaccines. Cancer Immunol Immunother 1998; 46: 82–87
   PubMed Web of Science ®Google Scholar
• Gong J, Chen D, Kashiwara M. Induction of antitumor activity by immunization with fusion of dendritic and carcinoma cells. Nat Med 1997; 3: 588–561
   Google Scholar